EyePoint Pharmaceuticals Inc
EYPT11.210USD
+0.130+1.17%
Fechamento 11/07, 16:00（ET）Cotações atrasadas em 15 min
779.88MValor de mercado
PerdaP/L TTM
Mais detalhes de EyePoint Pharmaceuticals Inc Empresa
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the business of developing and commercializing ophthalmic products for the treatment of eye diseases. The Company's pipeline leverages its Durasert technology (Durasert) for sustained intraocular drug delivery, including delivery of EYP-1901, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases. Its additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. EYP-1901 is presently in Phase 2 clinical trials as a sustained delivery treatment for wet age-related macular degeneration (wet AMD), no proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The Company’s other products include YUTIQ, and DEXYCU.
Informações de EyePoint Pharmaceuticals Inc
Código da empresaEYPT
Nome da EmpresaEyePoint Pharmaceuticals Inc
Data de listagemJan 27, 2005
CEODr. Jay S. Duker, M.D.
Número de funcionários165
Tipo de títulosOrdinary Share
Fim do ano fiscalJan 27
Endereço480 Pleasant Street, Suite C400
CidadeWATERTOWN
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal02472
Telefone16179265000
Sitehttps://eyepointpharma.com/
Código da empresaEYPT
Data de listagemJan 27, 2005
CEODr. Jay S. Duker, M.D.
Executivos da empresa EyePoint Pharmaceuticals Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Jay S. Duker, M.D.
Dr. Jay S. Duker, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
685.61K
+1.33%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Executive Vice Chairman of the Board
Executive Vice Chairman of the Board
575.46K
+1.97%
Dr. John B. Landis, Ph.D.
Dr. John B. Landis, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
142.86K
+567.59%
Ms. Karen L. Zaderej
Ms. Karen L. Zaderej
Non-Executive Independent Director
Non-Executive Independent Director
117.28K
+1.73%
Ms. Wendy F. Dicicco, CPA
Ms. Wendy F. Dicicco, CPA
Non-Executive Independent Director
Non-Executive Independent Director
107.43K
+977.87%
Mr. Stuart Duty
Mr. Stuart Duty
Non-Executive Independent Director
Non-Executive Independent Director
45.01K
--
Mr. Ramiro Ribeiro, M.D., Ph.D.
Mr. Ramiro Ribeiro, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
41.78K
--
Dr. Reginald J Sanders, M.D.
Dr. Reginald J Sanders, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Fred Hassan
Mr. Fred Hassan
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Stern
Mr. Stern
Investor Relations
Investor Relations
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Jay S. Duker, M.D.
Dr. Jay S. Duker, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
685.61K
+1.33%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Executive Vice Chairman of the Board
Executive Vice Chairman of the Board
575.46K
+1.97%
Dr. John B. Landis, Ph.D.
Dr. John B. Landis, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
142.86K
+567.59%
Ms. Karen L. Zaderej
Ms. Karen L. Zaderej
Non-Executive Independent Director
Non-Executive Independent Director
117.28K
+1.73%
Ms. Wendy F. Dicicco, CPA
Ms. Wendy F. Dicicco, CPA
Non-Executive Independent Director
Non-Executive Independent Director
107.43K
+977.87%
Mr. Stuart Duty
Mr. Stuart Duty
Non-Executive Independent Director
Non-Executive Independent Director
45.01K
--
Detalhamento da receita
Moeda: USDAtualizado em: seg, 6 de out
Moeda: USDAtualizado em: seg, 6 de out
FY2024
FY2023
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por EmpresaUSD
Nome
Receita
Proporção
YUTIQ
3.10M
7.16%
Por RegiãoUSD
Nome
Receita
Proporção
United States
42.05M
97.17%
China
1.12M
2.60%
United Kingdom
100.00K
0.23%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
YUTIQ
3.10M
7.16%
Distribuição de ações
Atualizado em: sáb, 16 de ago
Atualizado em: sáb, 16 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Cormorant Asset Management, LP
10.06%
Suvretta Capital Management, LLC
8.22%
Adage Capital Management, L.P.
8.21%
BlackRock Institutional Trust Company, N.A.
5.56%
Franklin Advisers, Inc.
5.15%
Outro
62.80%
Investidores
Investidores
Proporção
Cormorant Asset Management, LP
10.06%
Suvretta Capital Management, LLC
8.22%
Adage Capital Management, L.P.
8.21%
BlackRock Institutional Trust Company, N.A.
5.56%
Franklin Advisers, Inc.
5.15%
Outro
62.80%
Tipos de investidores
Investidores
Proporção
Hedge Fund
33.33%
Investment Advisor
23.07%
Investment Advisor/Hedge Fund
20.71%
Research Firm
3.68%
Individual Investor
2.96%
Venture Capital
2.92%
Private Equity
1.68%
Bank and Trust
0.95%
Pension Fund
0.14%
Outro
10.56%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
378
69.28M
83.75%
-19.64M
2025Q2
385
78.45M
113.85%
-10.49M
2025Q1
386
76.27M
110.90%
-11.90M
2024Q4
373
75.75M
111.39%
+202.32K
2024Q3
358
60.55M
112.89%
-8.01M
2024Q2
345
60.80M
116.35%
-2.75M
2024Q1
328
57.32M
114.97%
+528.95K
2023Q4
282
52.72M
108.16%
+11.49M
2023Q3
239
37.39M
106.16%
-1.26M
2023Q2
224
35.30M
102.90%
-4.83M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Cormorant Asset Management, LP
8.32M
12.08%
--
--
Jun 30, 2025
Suvretta Capital Management, LLC
6.80M
9.87%
--
--
Jun 30, 2025
Adage Capital Management, L.P.
6.80M
9.87%
+600.00K
+9.68%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.60M
6.67%
-346.31K
-7.00%
Jun 30, 2025
Franklin Advisers, Inc.
4.27M
6.19%
+148.48K
+3.60%
Jun 30, 2025
The Vanguard Group, Inc.
3.80M
5.52%
-15.98K
-0.42%
Jun 30, 2025
Federated Hermes Global Investment Management Corp.
3.58M
5.2%
-128.17K
-3.45%
Jun 30, 2025
TCG Crossover Management, LLC
3.57M
5.18%
--
--
Jun 30, 2025
Citadel Advisors LLC
2.34M
3.4%
+58.12K
+2.54%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.59M
2.31%
-982.00
-0.06%
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: qui, 6 de nov
Atualizado em: qui, 6 de nov
Nome
Proporção
Virtus LifeSci Biotech Clinical Trials ETF
1.16%
Simplify Health Care ETF
1.02%
SPDR S&P Pharmaceuticals ETF
0.98%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.73%
Invesco Dorsey Wright SmallCap Momentum ETF
0.39%
Federated Hermes MDT Small Cap Core ETF
0.3%
iShares Micro-Cap ETF
0.16%
Invesco Nasdaq Biotechnology ETF
0.1%
Vanguard US Momentum Factor ETF
0.1%
ProShares Ultra Nasdaq Biotechnology
0.1%
Ver Mais
Virtus LifeSci Biotech Clinical Trials ETF
Proporção1.16%
Simplify Health Care ETF
Proporção1.02%
SPDR S&P Pharmaceuticals ETF
Proporção0.98%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporção0.73%
Invesco Dorsey Wright SmallCap Momentum ETF
Proporção0.39%
Federated Hermes MDT Small Cap Core ETF
Proporção0.3%
iShares Micro-Cap ETF
Proporção0.16%
Invesco Nasdaq Biotechnology ETF
Proporção0.1%
Vanguard US Momentum Factor ETF
Proporção0.1%
ProShares Ultra Nasdaq Biotechnology
Proporção0.1%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Dec 08, 2020
Merger
10→1
Dec 08, 2020
Merger
10→1
Dec 08, 2020
Merger
10→1
Dec 08, 2020
Merger
10→1
Data
Tipo
Proporção
Dec 08, 2020
Merger
10→1
Dec 08, 2020
Merger
10→1
Dec 08, 2020
Merger
10→1
Dec 08, 2020
Merger
10→1
